U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H8NO5.K
Molecular Weight 237.2514
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CLAVULANATE POTASSIUM

SMILES

C(\[H])(=C/1\[C@]([H])(C(=O)[O-])N2C(=O)C[C@@]2([H])O1)/CO.[K+]

InChI

InChIKey=ABVRVIZBZKUTMK-JSYANWSFSA-M
InChI=1S/C8H9NO5.K/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4;/h1,6-7,10H,2-3H2,(H,12,13);/q;+1/p-1/b4-1-;/t6-,7-;/m1./s1

HIDE SMILES / InChI

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C8H8NO5
Molecular Weight 198.1531
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED

drug resistance to penicillins and cephalosporins. Clavulanic acid is used in conjunction with amoxicillin for the treatment of bronchitis and urinary tract, skin, and soft tissue infections caused by beta-lactamase producing organisms. Clavulanic acid competitively and irreversibly inhibits a wide variety of beta-lactamases, commonly found in microorganisms resistant to penicillins and cephalosporins. Binding and irreversibly inhibiting the beta-lactamase results in a restauration of the antimicrobial activity of beta-lactam antibiotics against lactamase-secreting-resistant bacteria. By inactivating beta-lactamase (the bacterial resistance protein), the accompanying penicillin/cephalosporin drugs may be made more potent as well.

CNS Activity

Curator's Comment:: Clavulanic acid is a CNS-modulating compound with exceptional blood-brain barrier permeability and safety profile. Clavulanic acid has been proposed to have anti-depressant activity and was in Phase IIb clinical trials for the treatment of Major Depressive Disorder (MDD). Studies have also shown that clavulanic acid suppresses anxiety and enhances sexual functions in rodent and primate models by a mechanism involving central nervous system (CNS) modulation.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Augmentin

Approved Use

AUGMENTIN is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Otitis Media – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Sinusitis – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Skin and Skin Structure Infections – caused by β-lactamase–producing strains of S. aureus, E. coli, and Klebsiella spp. Urinary Tract Infections – caused by β-lactamase–producing strains of E. coli, Klebsiella spp. and Enterobacter spp.

Launch Date

832118400000
Curative
Augmentin

Approved Use

AUGMENTIN is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Otitis Media – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Sinusitis – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Skin and Skin Structure Infections – caused by β-lactamase–producing strains of S. aureus, E. coli, and Klebsiella spp. Urinary Tract Infections – caused by β-lactamase–producing strains of E. coli, Klebsiella spp. and Enterobacter spp.

Launch Date

832118400000
Curative
Augmentin

Approved Use

AUGMENTIN is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Otitis Media – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Sinusitis – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Skin and Skin Structure Infections – caused by β-lactamase–producing strains of S. aureus, E. coli, and Klebsiella spp. Urinary Tract Infections – caused by β-lactamase–producing strains of E. coli, Klebsiella spp. and Enterobacter spp.

Launch Date

832118400000
Curative
Augmentin

Approved Use

AUGMENTIN is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Otitis Media – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Sinusitis – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Skin and Skin Structure Infections – caused by β-lactamase–producing strains of S. aureus, E. coli, and Klebsiella spp. Urinary Tract Infections – caused by β-lactamase–producing strains of E. coli, Klebsiella spp. and Enterobacter spp.

Launch Date

832118400000
Curative
Augmentin

Approved Use

AUGMENTIN is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Otitis Media – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Sinusitis – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Skin and Skin Structure Infections – caused by β-lactamase–producing strains of S. aureus, E. coli, and Klebsiella spp. Urinary Tract Infections – caused by β-lactamase–producing strains of E. coli, Klebsiella spp. and Enterobacter spp.

Launch Date

832118400000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.63 μg/mL
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered: AMOXICILLIN
CLAVULANIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.49 μg × h/mL
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered: AMOXICILLIN
CLAVULANIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1 h
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered: AMOXICILLIN
CLAVULANIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg/kg 1 times / day steady, oral
Recommended
dose: 10 mg/kg 1 times / day
route: oral
experiment_type: steady
dose_type: Recommended
co-adm with
    data_source:
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf
    unhealthy, 2 months to 12 years
    Other AEs: Diarrhea, Rash urticarial...
    125 mg 1 times / day steady, oral
    Recommended
    dose: 125 mg 1 times / day
    route: oral
    experiment_type: steady
    dose_type: Recommended
    co-adm with
      data_source:
      https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf
      unhealthy, adult
      Other AEs: Loose stools, Nausea...
      AEs

      AEs

      AESignificanceDosePopulation
      Diaper rash
      10 mg/kg 1 times / day steady, oral
      Recommended
      dose: 10 mg/kg 1 times / day
      route: oral
      experiment_type: steady
      dose_type: Recommended
      co-adm with
        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf
        unhealthy, 2 months to 12 years
        Diarrhea
        10 mg/kg 1 times / day steady, oral
        Recommended
        dose: 10 mg/kg 1 times / day
        route: oral
        experiment_type: steady
        dose_type: Recommended
        co-adm with
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf
          unhealthy, 2 months to 12 years
          Rash urticarial
          10 mg/kg 1 times / day steady, oral
          Recommended
          dose: 10 mg/kg 1 times / day
          route: oral
          experiment_type: steady
          dose_type: Recommended
          co-adm with
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf
            unhealthy, 2 months to 12 years
            Vaginitis 1%
            125 mg 1 times / day steady, oral
            Recommended
            dose: 125 mg 1 times / day
            route: oral
            experiment_type: steady
            dose_type: Recommended
            co-adm with
              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf
              unhealthy, adult
              Vomiting 1%
              125 mg 1 times / day steady, oral
              Recommended
              dose: 125 mg 1 times / day
              route: oral
              experiment_type: steady
              dose_type: Recommended
              co-adm with
                data_source:
                https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf
                unhealthy, adult
                Nausea 3%
                125 mg 1 times / day steady, oral
                Recommended
                dose: 125 mg 1 times / day
                route: oral
                experiment_type: steady
                dose_type: Recommended
                co-adm with
                  data_source:
                  https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf
                  unhealthy, adult
                  Rash urticarial 3%
                  125 mg 1 times / day steady, oral
                  Recommended
                  dose: 125 mg 1 times / day
                  route: oral
                  experiment_type: steady
                  dose_type: Recommended
                  co-adm with
                    data_source:
                    https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf
                    unhealthy, adult
                    Loose stools 9%
                    125 mg 1 times / day steady, oral
                    Recommended
                    dose: 125 mg 1 times / day
                    route: oral
                    experiment_type: steady
                    dose_type: Recommended
                    co-adm with
                      data_source:
                      https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf
                      unhealthy, adult
                      PubMed

                      PubMed

                      TitleDatePubMed
                      In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium fortuitum and Mycobacterium chelonei to augmentin.
                      1986 Aug
                      In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium avium, Mycobacterium fortuitum, and Mycobacterium chelonae to ticarcillin in combination with clavulanic acid.
                      1987 Jan
                      Immunogenicity and allergenicity studies on two beta-lactam structures, a clavam, clavulanic acid, and a carbapenem: structure-activity relationships.
                      1988
                      In vitro activity of antimicrobial agents against mycobacteria.
                      1988
                      beta-Lactamase activity in mycobacteria including Mycobacterium avium and suppression of their growth by a beta-lactamase-stable antibiotic.
                      1995
                      Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?
                      1995 Dec
                      beta-Lactam drug allergens: fine structural recognition patterns of cephalosporin-reactive IgE antibodies.
                      1996 Jul-Aug
                      Suppression of the growth of six potentially-pathogenic mycobacteria by beta-lactam/beta-lactamase-inhibitors.
                      1997
                      A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.
                      2014 Jan
                      Patents

                      Sample Use Guides

                      Adults
                      Route of Administration: Oral
                      The purified beta-lactamase enzyme focused at pI 5.4 and was strongly inhibited in vitro by clavulanic acid (IC50 = 0.09 uM).
                      Substance Class Chemical
                      Created
                      by admin
                      on Fri Jun 25 20:52:06 UTC 2021
                      Edited
                      by admin
                      on Fri Jun 25 20:52:06 UTC 2021
                      Record UNII
                      Q42OMW3AT8
                      Record Status Validated (UNII)
                      Record Version
                      • Download
                      Name Type Language
                      CLAVULANATE POTASSIUM
                      GREEN BOOK   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
                      USAN  
                      Official Name English
                      POTASSIUM CLAVULANATE
                      EP   MART.  
                      Common Name English
                      CLAVULANATE POTASSIUM COMPONENT OF CLAVULOX
                      Common Name English
                      BRL-14151K
                      Code English
                      POTASSIUM CLAVULANATE [EP MONOGRAPH]
                      Common Name English
                      CLAVULANATE POTASSIUM [GREEN BOOK]
                      Common Name English
                      POTASSIUM CLAVULANATE [MART.]
                      Common Name English
                      CLAVULANATE POTASSIUM [WHO-DD]
                      Common Name English
                      CLAVULANATE POTASSIUM COMPONENT OF TIMENTIN
                      Common Name English
                      CLAVULANATE POTASSIUM COMPONENT OF AUGMENTIN
                      Brand Name English
                      CLAVULANATE POTASSIUM [ORANGE BOOK]
                      Common Name English
                      TIMENTIN COMPONENT CLAVULANATE POTASSIUM
                      Common Name English
                      POTASSIUM CLAVULANATE [JAN]
                      Common Name English
                      CLAVULANATE POTASSIUM [USP MONOGRAPH]
                      Common Name English
                      CLAVULANATE POTASSIUM [USAN]
                      Common Name English
                      POTASSIUM (Z)-(2R,5R)-3-(2-HYDROXYETHYLIDENE)-7-OXO-4-OXA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLATE
                      Systematic Name English
                      BRL 14151K
                      Code English
                      CLAVULANIC ACID (AS CLAVULANATE POTASSIUM)
                      Common Name English
                      4-OXA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 3-(2-HYDROXYETHYLIDENE)-7-OXO-, MONOPOTASSIUM SALT, (2R-(2.ALPHA.,3Z,5.ALPHA.))-
                      Common Name English
                      CLAVULANATE POTASSIUM [VANDF]
                      Common Name English
                      CLAVULOX COMPONENT CLAVULANATE POTASSIUM
                      Common Name English
                      AUGMENTIN COMPONENT CLAVULANATE POTASSIUM
                      Brand Name English
                      Classification Tree Code System Code
                      CFR 21 CFR 520.88G
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      NCI_THESAURUS C260
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      CFR 21 CFR 520.88H
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      Code System Code Type Description
                      FDA UNII
                      Q42OMW3AT8
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      PRIMARY
                      EPA CompTox
                      61177-45-5
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      PRIMARY
                      EVMPD
                      SUB12232MIG
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      PRIMARY
                      ECHA (EC/EINECS)
                      262-640-9
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      PRIMARY
                      PUBCHEM
                      23665591
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      PRIMARY
                      ChEMBL
                      CHEMBL777
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      PRIMARY
                      CAS
                      61177-45-5
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      PRIMARY
                      DRUG BANK
                      DBSALT001302
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      PRIMARY
                      RXCUI
                      831418
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      PRIMARY RxNorm
                      NCI_THESAURUS
                      C47453
                      Created by admin on Fri Jun 25 20:52:06 UTC 2021 , Edited by admin on Fri Jun 25 20:52:06 UTC 2021
                      PRIMARY
                      Related Record Type Details
                      PARENT -> SALT/SOLVATE
                      Related Record Type Details
                      IMPURITY -> PARENT
                      CHROMATOGRAPHIC PURITY (GC)
                      USP
                      Related Record Type Details
                      ACTIVE MOIETY